Abstract
The discovery and development of selective, efficacious, and safe small molecule p38 mitogen-activated protein kinase inhibitors for the treatment of inflammatory diseases remains the focus of many pharmaceutical research programs. Advances in small molecule p38 inhibitor design in potency and oral efficacy have been accelerated with the large number of available inhibitor-enzyme x-ray structures. These advances have allowed for the discovery of diverse sets of inhibitors with the opportunity to map inhibitor interactions and design selective inhibitors. This review covers recent compound disclosures in the patent and published literature over the last three years. Many disclosures represent new chemotypes as well as creative modifications of known structures.
Keywords: mitogen activated protein (map), rheumatoid arthritis, aniline hydroxamates, x-ray crystallography, cyanopyrimidine, indole-amides
Current Topics in Medicinal Chemistry
Title: Small Molecule p38 Inhibitors: Novel Structural Features and Advances from 2002-2005
Volume: 5 Issue: 10
Author(s): John Hynes, Jr. and Katerina Leftheris
Affiliation:
Keywords: mitogen activated protein (map), rheumatoid arthritis, aniline hydroxamates, x-ray crystallography, cyanopyrimidine, indole-amides
Abstract: The discovery and development of selective, efficacious, and safe small molecule p38 mitogen-activated protein kinase inhibitors for the treatment of inflammatory diseases remains the focus of many pharmaceutical research programs. Advances in small molecule p38 inhibitor design in potency and oral efficacy have been accelerated with the large number of available inhibitor-enzyme x-ray structures. These advances have allowed for the discovery of diverse sets of inhibitors with the opportunity to map inhibitor interactions and design selective inhibitors. This review covers recent compound disclosures in the patent and published literature over the last three years. Many disclosures represent new chemotypes as well as creative modifications of known structures.
Export Options
About this article
Cite this article as:
Hynes, Jr. John and Leftheris Katerina, Small Molecule p38 Inhibitors: Novel Structural Features and Advances from 2002-2005, Current Topics in Medicinal Chemistry 2005; 5 (10) . https://dx.doi.org/10.2174/1568026054985920
DOI https://dx.doi.org/10.2174/1568026054985920 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Skeletal Survey in Multiple Myeloma: Role of Imaging
Current Medical Imaging Inflammation in Cardiovascular Disease and Regulation of the Actin Cytoskeleton in Inflammatory Cells: The Actin Cytoskeleton as a Target
Cardiovascular & Hematological Agents in Medicinal Chemistry Effects of Drug Transporters on Pharmacological Responses and Safety
Current Drug Metabolism Rho GTPases: Promising Cellular Targets for Novel Anticancer Drugs
Current Cancer Drug Targets Regulation of Bcl-2 Family Proteins by Posttranslational Modifications
Current Molecular Medicine High Throughput Screening for Colorectal Cancer Specific Compounds
Combinatorial Chemistry & High Throughput Screening DNA Damage-inducing Compounds: Unraveling their Pleiotropic Effects Using High Throughput Sequencing
Current Medicinal Chemistry One Special Question to Start with: Can HIF/NFkB be a Target in Inflammation?
Endocrine, Metabolic & Immune Disorders - Drug Targets The Influence of Cox-2 and Bioactive Lipids on Hematological Cancers
Current Angiogenesis (Discontinued) Modulation of Angiogenesis by Inflammatory Markers and the Role of Matrix Metalloproteinases in an Endothelial Cell/Fibroblast Co-culture System
Current Angiogenesis (Discontinued) Selectively Targeted Anti-Neoplastic Cytotoxicity of Three Immunopharmaceuticals with Covalently Bound Fludarabine, Gemcitabine and Dexamethasone Moieties Synthesized Utilizing Organic Chemistry Reactions in a Multi-Stage Regimen
Current Pharmaceutical Design Modifications of Cell Signalling and Redox Balance by Targeting Protein Acetylation Using Natural and Engineered Molecules: Implications in Cancer Therapy
Current Topics in Medicinal Chemistry Targeting CD4 to Disrupt Signaling Through Membrane Rafts: Towards a Raft-Based Therapeutics
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Could Resveratrol be a Useful Drug for the Treatment of Malignant Hemopathies?
Recent Patents on Anti-Cancer Drug Discovery Identification of Phosphoproteins and their Impact as Biomarkers in Cancer Therapeutics
Current Signal Transduction Therapy Genetic and Epigenetic Studies for Determining Molecular Targets of Natural Product Anticancer Agents
Current Cancer Drug Targets Osteoclasts and Remodeling Based Bone Formation
Current Stem Cell Research & Therapy Modulating Co-Stimulation During Antigen Presentation to Enhance Cancer Immunotherapy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Small Molecules Targeting Mutant P53: A Promising Approach for Cancer Treatment
Current Medicinal Chemistry The Role of Nucleoside Transport in the Antineoplastic Activity of Purine Nucleoside Chemotherapeutic Agents
Current Cancer Therapy Reviews